Researchers at Oregon Health & Science University reported that combining venetoclax with palbociclib produced stronger and more durable anti‑leukemia activity in AML models than venetoclax alone. The Cell Reports Medicine paper details tests across patient samples and mouse xenografts showing the CDK4/6 inhibitor mitigates resistance mechanisms to the BCL2 inhibitor. The preclinical work identifies co‑targeting cell‑cycle and protein‑synthesis pathways as a route to overcome venetoclax resistance and provides a rationale for clinical testing of the combination in AML patients who relapse on standard regimens.